What is the purpose of an Investigational New Drug (IND) application?

Study for the Clinical Research and Ethical Considerations Test. Enhance your understanding with multiple choice questions covering essential ethical guidelines and research methodologies. Prepare effectively for your test!

Multiple Choice

What is the purpose of an Investigational New Drug (IND) application?

An IND is a regulatory submission to the FDA that seeks permission to begin testing a new drug in humans in the United States. It shows that there is enough preclinical safety data, describes how the drug is manufactured to ensure quality, and outlines the proposed clinical trial protocols and investigator qualifications. This process is in place to protect volunteers by making sure the study is scientifically sound and that risks are minimized before any human testing occurs. It is required before initiating trials in the U.S., and the FDA can place a hold if safety concerns or data gaps are found. The other options don’t fit because they address different functions. An internal document outlining marketing strategy has nothing to do with regulatory authorization to test a drug. An ethical review by an IRB focuses on participant protection and study ethics, not the FDA’s approval to start trials. Registration of a trial in ClinicalTrials.gov is a public disclosure action, not the regulatory approval to begin testing.

An IND is a regulatory submission to the FDA that seeks permission to begin testing a new drug in humans in the United States. It shows that there is enough preclinical safety data, describes how the drug is manufactured to ensure quality, and outlines the proposed clinical trial protocols and investigator qualifications. This process is in place to protect volunteers by making sure the study is scientifically sound and that risks are minimized before any human testing occurs. It is required before initiating trials in the U.S., and the FDA can place a hold if safety concerns or data gaps are found.

The other options don’t fit because they address different functions. An internal document outlining marketing strategy has nothing to do with regulatory authorization to test a drug. An ethical review by an IRB focuses on participant protection and study ethics, not the FDA’s approval to start trials. Registration of a trial in ClinicalTrials.gov is a public disclosure action, not the regulatory approval to begin testing.

More practice questions